Evidence map›Paper›PMID 28029009›Full record

ArticleAnnals of laboratory medicine2017

Susceptibility of Ceftolozane-Tazobactam and Ceftazidime-Avibactam Against a Collection of β-Lactam-Resistant Gram-Negative Bacteria.

Mark D Gonzalez, Allison R McMullen, Meghan A Wallace, Matthew P Crotty, David J Ritchie, Carey Ann D Burnham

Abstract readLetter
PubMed Full text at PMC Publisher
In one paragraph

Article in Annals of laboratory medicine, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
12citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

12 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Article
  3. Article
  4. Review
  5. Article
  6. New Perspectives on Antimicrobial Agents: Ceftolozane-Tazobactam.Antimicrobial agents and chemotherapy · 2021
    Review
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Evaluation of in vitro activity of ceftolozane-tazobactam against recent clinical bacterial isolates from Brazil - the EM200 study.The Brazilian journal of infectious diseases : an official publication of the Brazilian Society of Infectious Diseases
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Mark D GonzalezDepartment of Pathology and Immunology, Division of Laboratory and Genomic Medicine, Washington University School of Medicine, St. Louis, MO, USA.
Allison R McMullenDepartment of Pathology and Immunology, Division of Laboratory and Genomic Medicine, Washington University School of Medicine, St. Louis, MO, USA.
Meghan A WallaceDepartment of Pathology and Immunology, Division of Laboratory and Genomic Medicine, Washington University School of Medicine, St. Louis, MO, USA.
Matthew P CrottyPharmacy Department, Barnes-Jewish Hospital, St. Louis, MO, USA.
David J RitchiePharmacy Department, Barnes-Jewish Hospital, St. Louis, MO, USA.
Carey Ann D BurnhamDepartment of Pathology and Immunology, Division of Laboratory and Genomic Medicine, Washington University School of Medicine, St. Louis, MO, USA.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

Anti-Bacterial AgentsAzabicyclo CompoundsBacterial ProteinsCeftazidimeCephalosporinsDNA, BacterialDrug CombinationsDrug Resistance, BacterialGram-Negative BacteriaHumansMicrobial Sensitivity TestsPenicillanic AcidPseudomonas aeruginosaReal-Time Polymerase Chain ReactionTazobactamAnti-Bacterial Agentsavibactam, ceftazidime drug combinationAzabicyclo CompoundsBacterial ProteinsCeftazidimeceftolozane, tazobactam drug combinationCephalosporinsDNA, BacterialDrug CombinationsPenicillanic AcidTazobactam

Identifiers

PMID28029009
PMCPMC5204000

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.